Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q4 2024 Earnings Presentation
25 slides from Revenio Group Oyj's earnings presentation, Feb 13, 2025
Slide 1: 2024 Financial Statements Release
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION 2024 Financial Statements Release February 13, 2025 1 13.2.2025 Revenio
Slide 2: Disclaimer
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporations' shares. Group's past performance is no guide to future performance, and persons needing advi
Slide 3: We aspire to keep the wonderful world visible for all
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION We aspire to keep the wonderful world visible for all. 3 13.2.2025 Revenio
Slide 4: Today's presenters
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Today’s presenters Jouni Robin Toijala Pulkkinen CEO CFO 4 13.2.2025 Revenio
Slide 5: Agenda
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Agenda 1. Business Highlights 2. Strategy period 2024–2026 recap 3. Financials of Q4 and 2024 4. Financial guidance for 2025 5. Summary: Revenio as an investment 6. Q&A 5 13.2.2025 Revenio
Slide 6: Strong operating cash flow and profitability in challenging market conditions
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Strong operating cash flow and profitability in challenging market conditions Net sales EBIT • Last quarter culminated in an all-time sales record in December 30.5 9.1 • Profitability was strong in the fourth quarter of MEUR (+4.8%) MEUR (-3.6%) the ye
Slide 7: Strategy period 2024–2026 recap
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Strategy period 2024–2026 recap 7 13.2.2025 Revenio
Slide 8: Despite the geopolitical and economical turmoil megatrends support our growth
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Despite the geopolitical and economical turmoil megatrends support our growth The need for eye care Insufficient eye care We need smarter is growing globally workforces ways of working 8 13.2.2025 Revenio
Slide 9: Growing scale towards connected and predictive eye care pathways 2024–2026
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Growing scale towards connected and predictive eye care pathways 2024–2026 ESG Improve the quality Enhance customer of clinical diagnostics focus with targeted product in operations & sales innovations Keeping the Wonderful World Develop People & Visib
Slide 10: In 2024 significant advancements in all strategic areas
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION In 2024 significant advancements in all strategic areas Improve the quality of clinical • Sales started for iCare ST500, iCare TONOVET Pro and iCare TONOVET Pet diagnostics with Targeted • iCare MAIA launch product innovations • China marketing authori
Slide 11: Our key priorities 2025 onwards
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Our key priorities 2025 onwards Our growth pathway 2024–2026 We invest in R&D We expand our We develop further We continue search Our ESG program to launch new offering to non- customer for selected is maturing, and we and exciting traditional eye care
Slide 12: Financials Q4 and 2024
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Financials Q4 and 2024 12 13.2.2025 Revenio
Slide 13: Development of Revenio's key figures
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Development of Revenio’s key figures MEUR 10-12/ 10-12/ Change 1-12/ 1-12/ Change 2024 2023 -% 2024 2023 -% Net sales 30.5 29.1 4.8 103.5 96.6 7.2 Strong profitability and cash flow Gross margin 21.7 20.5 5.8 72.9 68.2 6.9 in the fourth quarter. Gross
Slide 14: Return to the growth path
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Return to the growth path Net sales (EUR million) 35 30,5 30 28,3 29,1 Our reported sales grew 7.2 25,4 percentage points during 2024 24,4 24,1 23,9 25 23,8 23,2 22,3 22,0 23,6 and 4.8% in Q4/24. 20,2 20 Recurring revenue from software 15 licenses, ser
Slide 15: 2024 finished with strong profitability
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION 2024 finished with strong profitability Adjusted operating profit EUR million and % (EBIT) 10 9,5 35 9,3 9,3 9 Cost increases year over year are 30 mostly related to higher bonus 8 7,7 7,7 7,1 accruals and salaries as well as IT 7 25 6,2 6,2 & marketin
Slide 16: Unleveraged balance sheet creates flexibility
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Unleveraged balance sheet creates flexibility 90% 80% 76,2 % 72,7 % 70% 66,8 % 63,0 % 60,9 % 60% 50% 40% 30,6 % 31,2 % 29,7 % 28,2 % 28,3 % 30% 25,1 % 22,4 % 23,5 % 22,1 % 18,1 % 20% 10% 0% -2,4 % -1,0 % -3,6 % -10% -7,3 % -13,1 % -20% 2020 2021 2022 2
Slide 17: Solid and cash-generating business model
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Solid and cash-generating business model Cash flow from operations In 2024 our cash flow from operating activities 30 EUR Millions totaled EUR 23.9 (10.9) million. More efficient working capital management was the main driver for 25 23,9 23,2 the posit
Slide 18: Continuously investing into growth and competitive new products
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Continuously investing into growth and competitive new products 14 11,3 12 10,8 % EUR Millions 10,0 12 10 We continue to invest in R&D to ensure 8,9 8,5 8,3 10,4 10,4 competitiveness. In our investments we have full 10 7,5 8 focus on the eye care marke
Slide 19: We are one of the best performing companies in our field
We are one of the best performing companies in our field Net sales growth, %* EBIT growth, %* EBIT margin, %* 25% 40,0 % 35,0 % 30,0 % 30,0 % 20% 20,0 % 25,0 % 15% 20,0 % 10,0 % 10% 15,0 % 0,0 % 2022 2023 H1/2024 5% 10,0 % -10,0 % 0% 5,0 % -20,0 % 2022 2023 H1/2024 0,0 % -5% -30,0 % 2021 2022 2023 H
Slide 20: Strong financial development has enabled a steadily increasing dividend
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Strong financial development has enabled a steadily increasing dividend combined with a lowering payout ratio 0,40 0,40 140% 0,38 0,36 0,35 0,34 120% 0,32 105,8 % 0,30 Revenio BoD will propose to the 0,30 0,28 100% 2025 AGM that a dividend of 0,26 0,25
Slide 21: Shareholders on December 31, 2024
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Shareholders on December 31, 2024* No. of shares % Verified Ownership 1. William Demant Invest A/S 5,229,023 19.60% 2024-12-31 2. SEB Investment Management 1,140,063 4.27% 2024-12-31 3. Vanguard 895,331 3.36% 2024-12-31 4. Swedbank Robur Funds 749,000
Slide 22: We are committed to sustainable and profitable growth
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION We are committed to sustainable and profitable growth Market growth Targeted revenue growth The relevant global market for Revenio is the market Revenio is targeting to reach a growth rate of for eye diagnostic devices, which has an average 3 times fas
Slide 23: Financial guidance for 2025
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Financial guidance for 2025 Revenio Group’s exchange rate-adjusted net sales are estimated to grow 6-15 percent from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level. 23 13.2.2025 Revenio
Slide 24: Q&A
FINANCIAL STATEMENTS 2024 - RESULT PRESENTATION Q&A 24 13.2.2025 Revenio
Slide 25: Revenio
REVENIO